Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 35 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/1/1994


1.		Phase III, Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Sequentially Administered IL-3 and G-CSF vs G-CSF Alone in Patients with Hodgkin's Disease or non-Hodgkin's Lymphoma Who Have Undergone ABMT (Summary Last Modified 11/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 and over								MSKCC-93163 NCI-V94-0466

Last Modified: 7/11/2007


2.		Phase III Randomized Comparison of Low-Dose ARA-C vs ARA-C/GM-CSF vs ARA-C/IL-3 in Patients with High-Risk Myelodysplastic Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 to 80								EORTC-06903

Last Modified: 5/23/2007 First Published: 9/1/2000


3.		Phase I/II Randomized Study of Ex Vivo Expanded Megakaryocytes in Patients With Breast Cancer or Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 to 60				Other				NU-97B2 NCI-V00-1611, NCT00006225

Last Modified: 11/1/1990


4.		Phase I/II Randomized Multicenter Study of IL-3 in Patients with Myelodysplastic Syndromes at Relatively Low Risk of Developing Acute Leukemia (Summary Last Modified 11/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				over 18								EORTC-06891

Last Modified: 7/12/2007


5.		Phase I/II Pilot, Multicenter Study of Recombinant Human IL-3 plus Low-Dose ARA-C in Patients with Myelodysplastic Syndrome Who Are at High Risk of Developing Acute Leukemia (Summary Last Modified 05/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				15 to 80								EORTC-06902

Last Modified: 9/1/1991


6.		Phase I/II Pilot Study of IL-3 Following High-Dose Intravenous CDDP/CTX and Intraperitoneal CBDCA/VP-16 as Primary Treatment in Patients with Stage II/III/IV Ovarian Carcinoma (Summary Last Modified 09/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over								MSKCC-90154 NCI-V91-0100

Last Modified: 11/1/1993


7.		Phase I/II Study of IL-3 plus G-CSF in Patients with Relapsed or Refractory Germ Cell Tumors Receiving Chemotherapy with CDDP/IFF/VP-16 or CDDP/IFF/VBL (Summary Last Modified 11/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over								MSKCC-93017 NCI-V93-0271

Last Modified: 8/1/1999


8.		Phase II Pilot Study of MDR-1 Retrovirus-Transduced Peripheral Blood Stem Cells for Chemoprotection During Therapy for Advanced Breast Cancer (Summary Last Modified 08/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 to 60				NCI				MDA-DM-94028 NCI-T95-0064D, T95-0064

Last Modified: 11/13/2007


9.		Phase II Pilot Study of High-Dose Ifosfamide/Carboplatin/Etoposide (ICE) Followed by Transplantation with neo-r-Transduced Autologous Bone Marrow and PBSC for Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 to 60				NCI				NCI-92-C-0161I NCI-MB-294, NCI-T92-0018N, T92-0018

Last Modified: 11/7/2007


10.		Phase II Study of High-Dose L-PAM and TBI with Autologous Bone Marrow and PBSC Support Followed by IFN-A for Multiple Myeloma, with Genetic Marking with Retroviral Vectors to Study the Feasibility of Stem Cell Gene Transfer and the Biology of Hematologic Reconstitution

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				up to 65				NHLBI				NHLBI-92-H-57 NCI-T92-0139N, T92-0139

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute